Available evidence shows that the direct β-cell damage [28], inflammation-induced insulin resistance [29], hypokalemia-related inhibition of insulin secretion by β-cells [30] and corticosteroid use in the treatment of COVID-19 contribute to the poor glycemic control in patients with DM who develop COVID-19 [3]. This evidence concerns the gene INS and COVID-19.